Partnerships & Mergers

Under the agreement, Novo Nordisk will internally assess Vivani’s investigational NPM-139 implant, which utilizes the company’s proprietary NanoPortal technology to deliver semaglutide continuously over extended periods through a miniature subdermal device.

Under the agreement, Everest Medicines will receive US$112.5 million upfront from Travere Therapeutics and could earn up to US$1.03 billion more in milestone payments if certain clinical, regulatory, and commercial goals are met across five indications.

The investment forms part of the hospital’s broader strategy to expand access to next-generation medical technologies despite Lebanon’s ongoing healthcare and economic challenges.

The new collaboration centres on CSPC’s small interfering RNA (siRNA) drug discovery platform and its proprietary delivery technology, which is designed to transport therapies beyond the liver.

The agreement also supports GlobeMed Gulf’s broader strategy of expanding access to high-quality healthcare for its growing base of insured members.

The initiative will support patients with the greatest medical and financial needs by improving access to advanced therapies within a framework aligned with the UAE’s national health insurance system.

The agreement builds on Haleon’s existing use of Microsoft 365 Copilot and broadens the company’s adoption of Microsoft’s AI, cloud and data technologies.

The collaboration aims to turn scientific discoveries into practical healthcare solutions by combining MIT’s research expertise with Abu Dhabi’s expanding life sciences ecosystem.

Under the collaboration, Insilico Medicine will use its proprietary Pharma.AI platform to identify and optimise drug candidates that meet predefined scientific and early development criteria.

Under the partnership, the two organizations will work together to enhance HMC’s Clinical Trials Unit (CTU), strengthen research expertise, and develop initiatives that support the continued growth of Qatar’s healthcare sector.